Baxter International BAX Emerging markets — Net Sales
Discontinued — last reported Q4 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Baxter International’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's emerging markets — net sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's emerging markets — net sales?
- Baxter International (BAX) reported emerging markets — net sales of $398M in Q4 2025.
- How has Baxter International's emerging markets — net sales changed year-over-year?
- Baxter International's emerging markets — net sales increased by 14.0% year-over-year, from $349M to $398M.
- What is the long-term trend for Baxter International's emerging markets — net sales?
- Over 3 years (2021 to 2025), Baxter International's emerging markets — net sales has grown at a -22.6% compound annual growth rate (CAGR), from $3.01B to $1.39B.
- What does emerging markets — net sales mean?
- Total revenue generated from sales in emerging geographic markets.
- How do you interpret emerging markets — net sales?
- An increase indicates successful market penetration and growing demand for medical solutions in developing regions, while a decrease may signal competitive pressure or economic headwinds in those territories.
- How does emerging markets — net sales compare across companies?
- Peers in the medical device sector typically report geographic revenue splits, with emerging market growth often serving as a key indicator of long-term global scaling potential.